VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE WITH A GLOBAL ANIMAL HEALTH VACCINE COMPANY
Nantes & Lyon (France) - 30 October 2012 - VIVALIS (NYSE Euronext: VLS) announced today that it has signed a new EB66® research license with a large, international animal health firm. The license allows for the assessment of up to six different viruses in EB66® cells. To date, this is the second EB66® license agreement signed with this company.
Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, "This new research license continues to validate our aggressive push into the animal vaccines market with EB66® cells. Evidenced by these efforts are five new license agreements over the past twelve months in the animal health field alone. As more organizations see the benefits of using EB66® cells over traditional manufacturing systems, we believe that EB66® cells will come to be a dominant standard in the manufacture of animal health vaccines, world-wide."
Financial terms of the agreement were not disclosed.
**********************
Next financial press release: 2013 Financial calendar
January 15, 2013, aftermarket closing
About VIVALIS (www.vivalis.com)
Vivalis (NYSE-Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs. Vivalis' expertise and intellectual property are leveraged in two main areas:
- EB66® Cell Line
Vivalis offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLPs and recombinant proteins, including monoclonal antibodies. Clinical trials of EB66® produced vaccines are currently on-going in the USA and Japan and in 2012 a vaccine produced in EB66® cells received market approval in Japan for use in animal health. Through these programs, Vivalis receives an upfront payment, clinical stage milestone payments along with royalties on licensees' net sales.
- VIVA|Screen(TM) Human Antibody Discovery Platform
Customized solutions for the discovery, development and production of rare, fully human monoclonal antibodies are offered by Vivalis. Through these programs, Vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical stage milestone payments along with royalties on net sales of licensed antibodies that are commercially developed from the use of the platform.
Based in Nantes and Lyon (France) and in Toyama (Japan), Vivalis was founded in 1999 by the Group Grimaud (approx. 1,700 employees), one of the worldwide leaders in animal genetic selection. Vivalis has established more than 30 partnerships and licenses with world leaders in biopharmaceutical industry, including Sanofi Pasteur, GlaxoSmithKline Biologicals, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.
| VIVALIS Listed on Euronext Paris - Compartment C of NYSE Euronext Reuters: VLS.PA - Bloomberg: VLS FP Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes |
This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's Document de Réference, changes in economic conditions, the financial markets or the markets in which the company operates.
Contacts
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communications agency
Axelle Vuillermet / Pierre Laurent Tel.: +33 (0) 1 44 71 94 93
Email: vivalis@newcap.fr
